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Introduction. This study evaluates the efficacy of palmitoylethanolamide ultramicronized (PEA-um) as an add-on treatment in
patients with diabetic or traumatic neuropathic pain (NP). Methods. 30 patients with chronic NP were assessed with Visual
Analogue Scale (VAS), NP Symptom Inventory (NPSI), and Health Questionnaire Five Dimensions (EQ-5D), both at baseline
and after 10 and 40 days of treatment with 1200mg/die of PEA-um. All other therapies were maintained stable during the follow-up
period. Results. VAS mean score significantly improved within the first 10 days, ranging from 8.20 ± 1.53 to 6.40 ± 1.83 (𝑃 < 0.002),
with a further decrease to 5.80 ± 2.04 (𝑃 < 0.001) after 40 days of PEA-um administration. Moreover, NPSI total score improved
from 5.2 ± 1.5 to 3.8 ± 2.1 (𝑃: 0.025) and EQ-5D ranged from −0.30 ± 0.65 to 0.5 ± 0.34 (𝑃 < 0.001) between T0 and T2. Conclusions.
This study reports the prospective short-term efficacy data of oral PEA-um in patients with diabetic or traumatic NP. A significant
improvement was observed both in VAS and NPSI scores and in quality of life scales after 40 days of treatment, although some
limitations should be considered, including the short followup and the open-label study design.
1. Introduction
Neuropathic pain (NP) due to nerve injury or neuronal
dysfunction could be associated with inflammatory reactions
and mobilization of the immune system cells [1]. Microglia
are thought to coordinate the inflammatory responses of
the central nervous system (CNS), while mast cells have a
pivotal role in the inflammatory responses of the peripheral
nervous system (PNS). Palmitoylethanolamide (PEA-um) is
an endogenous fatty acid, which can inhibit the release of
proinflammatory mediators from activated mast cells, reduc-
ing the recruitment and activation of mast cells at sites of
nerve injury [2]. PEA-um demonstrated a significant efficacy
on pain in the murine model of diabetic neuropathy [3].
However, few data are currently available in human subjects;
sporadic cases have been reported in the literature [4–8],
suggesting that PEA-um oral administration may lead to an
improvement of NP, reducing the allodynia and hyperalgesia.
In this context our aimwas to evaluate the clinical efficacy
of oral PEA-um treatment in a cohort of patientswith diabetic
or traumatic chronic NP, not adequately controlled by other
oral conventional therapies. Subjects were included in an
open label study, evaluating the efficacy of oral PEA-um
administration, as an add-on therapy, after 10 and 40 days of
therapy.
2. Materials and Methods
A cohort of 30 patients with diabetic or traumatic chronic
NP, not controlled by other oral conventional therapies, was
included in this study. All subjects suffered from a chronic
pain for at least 100 days at the time of recruitment, with
a Visual Analogue Scale (VAS) pain score higher than 6
[9], in spite of the best therapeutic regimen with Pregabalin,
Gabapentin, and/or Tramadol. All patients included in the
study were diagnosed as having an NP, according to the DN4
score ≥4, with an average score of 6.60 (range 4–9), and a
stable intensity of pain in the preceding 100 days.
After a preliminary screening, patients were asked to
participate at the study and then were evaluated by means of
VAS scale, NP Symptom Inventory (NPSI) [10], and health
questionnaire five dimensions (EQ-5D) for quality of life [11].
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Table 1: Clinical and demographic characteristics of patients at
baseline.
Diabetic neuropathy Traumatic neuropathy
Number of subjects 23 7
Gender 12 males 4 males
11 females 3 females
Age (years old) 63.87 ± 13.4 57.14 ± 7.5
VAS score 7.98 ± 1.7 8.57 ± 1.4
NPSI score 5.4 ± 1.6 4.9 ± 2.1
EQ-5D score −0.12 ± 0.35 −0.78 ± 1.03
Main clinical and demographic characteristics of patients affected by diabetic
neuropathy and traumatic neuropathy at baseline. VAS: Visual Analogue
Scale; NPSI: Neuropathic Pain Symptom Inventory; EQ-5D: health question-
naire five dimensions.
NPSI single items were also evaluated separately: burning
(superficial) spontaneous pain (Factor 1); pressing (deep)
spontaneous pain (Factor 2); paroxysmal pain (Factor 3);
evoked pain (Factor 4); paresthesia/dysesthesia (Factor 5).
This study was authorized by the scientific board of our
institute and all subjects signed a written informed consent.
Oral PEA-um treatment was initiated at the doses of
1200mg/die in sachet formulation for the first 10 days and
1200mg/die in tablet formulation between the 10th and 40th
days. The dosages of all other therapies were maintained
stable during the entire duration of the study.
After the first evaluation, performed at the time of
inclusion (T0), patients were reassessed at fixed intervals:
VAS evaluation was performed in all subjects after 10 days
of treatment (T1), while VAS, NPSI, EQ-5D, and DN4 were
repeated after 40 days of treatment (T2).
The statistical comparisons at different time points (T0,
T1, T2) were performed by means of Friedmann rank sum
test and where appropriate using Wilcoxon rank sum test.
A repeated measure ANOVA was performed in order to
evaluate whether patients responders to PEA-um had a
better outcome in the NPSI and EQ-5D scores. The analyses
were performed using PASWStat 18 for Windows. Data
are reported as mean values ± standard deviations and all
𝑃 values are two-tailed, considering 0.05 as the statistical
threshold.
3. Results
Themain clinical and demographic characteristics of patients
at baseline are reported in Table 1. During the study three
subjects dropped out for reasons not related to PEA-um
administration (one patient underwent surgery for colecis-
titis, one patient had a vertebral fracture, requiring hospital-
ization, and one patient had an intestinal virus); clinical data
were then available for 27 patients (14 males and 13 females);
20/27 subjects suffered from diabetic neuropathic pain, and
7/27 subjects were affected by neuropatic pain consequent to
brachial plexus traumatic lesions.
At T0 evaluation VAS mean score was 8.20 ± 1.53 (range
6–10), NPSI total score was 5.2±1.5 (range 2. 4–8.7), and EQ-
5D mean score was −0.30 ± 0.65 (range from −1.85 to 0.65).
At the first evaluation (T1) the VASmean score decreased
from 8.20 ± 1.53 to 6.4 ± 1.83 (range 2–10), reaching the
statistical threshold (𝑃 value < 0.002), and this improvement
was even more evident at the T2 evaluation (𝑃 value < 0.001),
with a further decrease in the mean VAS score to 5.80 ± 2.04
(range 2–10).
Moreover, as shown in Table 2, a significant improvement
was observed also in the NPSI total score, which decreased
from the T0 values of 5.2 ± 1.5 to the T2 values of 3.8 ± 2.1
(𝑃: 0.025), and a similar trend was observed for the EQ-5D
mean score, which increased from the T0 value of−0.30±0.65
to the T2 value of 0.50 ± 0.34 (𝑃 < 0.001). According to the
repeated measure ANOVA analysis, patients showing a VAS
scale improvement had a significantly better outcomes at the
NPSI (𝑃: 0.007) and at the EQ-5D (𝑃 < 0.001) scores.
A separate analysis of the NPSI different section scores
(Table 2) revealed that the most evident improvement was
achieved in section 5 of the scale, which refers to paresthesia
and dysesthesia (𝑃: 0.003).
4. Discussion
Brachial plexus neuropathy, with or without spinal cord root
avulsion, and diabetic neuropathy are both frequent causes of
NP,with a prevalence thatmay vary depending ondefinitions,
populations, and methodologies used for the assessment of
NP. Large international multicenter cohort studies [12, 13]
report a 10–30% prevalence of NP in diabetic patients, while
an Italian study described a 69% incidence of NP in 55
patients with traumatic plexopathies [14].
It has been reported that NP severity can affect the
patient’s quality of life more than neuropathic disability
and clinical severity [15], suggesting that its symptomatic
management might be one of the most important targets in
the treatment of peripheral neuropathies. However, in spite
of the relatively high prevalence, little consensus exists on the
best primary therapeutic choices in NP, also in view of the
multiple complexities underlying etiopathogenic factors.
PEA demonstrated a significant efficacy in reducing the
hyperalgesic component of NP [3, 16, 17], modulating the
activity ofmast cells.Moreover, PEAmight help to restore the
peripheral nerve sensitization process, induced by the release
of inflammatory cytokines at the site of nerve injury, through
a modulation of the endoneurial mast cells hyperactivity
[3]. However, the highly lipophilic PEA crystalline structure
has a poor oral adsorption, thus requiring to be micronized
and converted into particles with an elevated surface area to
volume ratio, in order to enhance its assimilation [18].
In this study, we report the first prospective short-term
data of oral PEA-um treatment in patients with diabetic or
traumatic NP. All subjects included in this protocol had been
already treated with Pregabalin, Gabapentin, or Tramadol,
with only partial improvement of symptoms and a significant
residual pain, as demonstrated by the VAS score higher than
6 at the time of recruitment.
Over the 40 days observational follow-up period, we
observed a significant improvement of VAS score, with
an initial reduction after 10 days of therapy and a further
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Table 2: Baseline to follow-up scores.
Baseline Followup 𝑃 value
VAS score 8.20 ± 1.53 5.80 ± 2.04 𝑃 < 0.001∗
NPSI total score 5.2 ± 1.5 3.8 ± 2.1 𝑃: 0.025∗
(i) Burning 7.2 ± 2.7 5.6 ± 3.2 𝑃: 0.063
(ii) Pressing 5.4 ± 2.9 4.0 ± 3.0 𝑃: 0.073
(iii) Paroxysmal pain 5.6 ± 3.1 4.0 ± 3.0 𝑃: 0.061
(iv) Evoked pain 3.7 ± 2.3 3.0 ± 2.2 𝑃: 0.279
(v) Paresthesia/dysesthesia 5.9 ± 2.6 3.6 ± 2.9 𝑃: 0.003∗
EQ-5D score −0.30 ± 0.65 0.50 ± 0.34 𝑃 < 0.001∗
A significant improvement was observed in the VAS and NPSI scores
between baseline and followup. Moreover, the NPSI subscores showed a
highly significant improvement for the paresthesia/dysesthesia subscore and
a trend towards amelioration for the other subscores.
VAS: Visual Analogue Scale; NPSI: Neuropathic Pain Symptom Inventory;
EQ-5D: health questionnaire five dimensions.
∗Indicates the statistical significance (𝑃 value < 0.05).
decrease at the end of the study. In addition, also the NPSI
score related to paresthesia and dysesthesia significantly
improved, as well as the quality of life measured with the EQ-
5D scale.
Overall, our findings would suggest that PEA-um oral
administration might be effective as an add-on therapy in
the control of NP, also resulting in an amelioration of patient
quality of life. However, two limitations should be considered
in the interpretations of our data: this study reports the
short-term follow-up data of a single center open-label study,
and the absence of a comparative group does not allow
speculations on the possible placebo effect in relieving pain.
Further larger prospective studies with longer follow-up
duration seem therefore necessary to confirm our findings
and the long-termpossible efficacy of oral PEA-um treatment
in the management of peripheral neuropathic pain.
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